Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Catonsville, Maryland Clinical Trials

A listing of Catonsville, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (155) clinical trials

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) dose of JNJ-26366821.

Phase

7.59 miles

Learn More »

A Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

The study will be a randomized, single-blind, placebo-controlled, single-ascending dose, sequential group study. This study part is planned to consist of 3 cohorts of Non-Asian subjects (Part 1) and 2 cohorts of Japanese subjects (Part 2). Part 2 will be initiated no earlier than after completion of the last Safety ...

Phase

7.59 miles

Learn More »

Safety Tolerability and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Part A To assess the safety and tolerability of single ascending oral doses of FB-101 in healthy subjects. To assess the pharmacokinetics (PK) of single ascending oral doses of FB-101 in healthy subjects. To assess the effect of a high-fat meal on the PK of a single oral dose of ...

Phase

7.59 miles

Learn More »

To Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.

This study is a Phase 1, randomized, single-blind, placebo-controlled, multiple dose group design in up to 33 male or female subjects with Type 2 diabetes and performed at 4 study centers. The planned number of cohorts is 3 but up to 5 cohorts may be included if the Safety Review ...

Phase

7.59 miles

Learn More »

A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine

Parts A and B will each have 2 Periods (Period 1 and Period 2) with a crossover design. Part B will be conducted only if results of Part A suggest a clinically meaningful effect of famotidine on savolitinib pharmacokinetics (PK) parameters. In both parts subjects will be randomly assigned 1:1 ...

Phase

7.59 miles

Learn More »

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

A total of 24 subjects are planned: 6 subjects in each of 4 cohorts: Cohort I (18 years), Cohort II (12 to <18 years), Cohort III (6 to <12 years), and Cohort IV (2 to <6 years). For Cohorts I and II, PK assessments of carisbamate, S-enantiomer and its R-enantiomer ...

Phase

7.64 miles

Learn More »

Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

OBJECTIVES Primary To evaluate safety, tolerability, and feasibility of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine with or without imiquimod in patients with human papillomavirus (HPV)16-positive grade 3 cervical intraepithelial neoplasia (CIN3). Secondary To evaluate the effect of this regimen on histology, based on the regression of cervical intraepithelial neoplasia. To ...

Phase

7.94 miles

Learn More »

Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment

This is an open-label, single-arm pilot study evaluating the antitumor activity and safety of niraparib as neoadjuvant therapy in patients with HER2 negative and BRCAmut localized breast cancer (primary tumor 1 cm).

Phase

7.94 miles

Learn More »

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) ...

Phase

7.97 miles

Learn More »

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

This primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies for whom no effective standard treatment is available.

Phase

7.97 miles

Learn More »